hims glp-1 california offers weight loss medications, injections and meal replacements Novo Nordisk Drops Hims &

A randomized controlled trial conducted on obese people has shown that a 12-week treatment with Liraglutide can reduce binge eating behavior and cause weigh loss in patients with binge eating disorder

GLP-1 Receptor (GLP-1R) Agonism Stimulates glucose-dependent insulin secretion: Enhances pancreatic beta-cell insulin release, thus lowering blood glucose 1,3,4

Effect of obesity and major weight reduction on gastric emptying

others may minimize an eating disorder to get or keep access to medication

Zepbound (tirzepatide): Patients on the 15 mg dose lost an average of 21% of their body weight over 72 weeks

The theoretical efficacy concern grows here, dropping to roughly 75% of standard dosing based on modeling